Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
825 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01781572 | A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma | completed | Phase 1 / Phase 2 | 102 | PfizerINDUSTRY | 5 | Dec 7, 2020 | clinicaltrials |
| NCT01684215 | A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer | completed | Phase 2 | 61 | PfizerINDUSTRY | 1 | Nov 23, 2020 |
| clinicaltrials |
| NCT02109653 | Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC | withdrawn | Phase 2 | 0 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT00553254 | Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer | completed | Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00821249 | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02092922 | A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) | completed | Phase 2 | 154 | PfizerINDUSTRY | 8 | Oct 19, 2020 | clinicaltrials |
| NCT00085787 | A Study of ARRY-142886 in Patients With Advanced Cancer | completed | Phase 1 | 57 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Oct 14, 2020 | clinicaltrials |
| NCT00278902 | A Study of ARRY-334543 in Patients With Advanced Cancer | completed | Phase 1 | 96 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 2 | Oct 14, 2020 | clinicaltrials |
| NCT01337765 | Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients | completed | Phase 1 | 29 | PfizerINDUSTRY | 5 | Oct 9, 2020 | clinicaltrials |
| NCT00637702 | A Study of ARRY-334543 in Patients With Advanced Cancer | completed | Phase 1 | 31 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Oct 8, 2020 | clinicaltrials |
| NCT00710736 | A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer | completed | Phase 1 | 29 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 2 | Oct 6, 2020 | clinicaltrials |
| NCT00833326 | A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer | completed | Phase 1 | 27 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Oct 6, 2020 | clinicaltrials |
| NCT01363232 | Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | completed | Phase 1 | 89 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 7 | Oct 5, 2020 | clinicaltrials |
| NCT01469130 | A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 21 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01248923 | A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 55 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT01352273 | MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations | completed | Phase 1 | 69 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 5 | Sep 30, 2020 | clinicaltrials |
| NCT00462358 | A Study of ARRY-520 in Patients With Advanced Cancer | completed | Phase 1 | 41 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 28, 2020 | clinicaltrials |
| NCT01999972 | A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors | completed | Phase 1 | 50 | PfizerINDUSTRY | 2 | Sep 24, 2020 | clinicaltrials |
| NCT01316822 | A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers | completed | Phase 1 | 26 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 21, 2020 | clinicaltrials |
| NCT00959127 | A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer | completed | Phase 1 | 93 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT01989325 | A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma | completed | Phase 2 | 77 | PfizerINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01649336 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | completed | Phase 1 | 36 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT03289533 | A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | completed | Phase 1 | 22 | PfizerINDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT02974868 | Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata | completed | Phase 2 | 142 | PfizerINDUSTRY | 3 | May 26, 2020 | clinicaltrials |
| NCT02659631 | PF-06671008 Dose Escalation Study in Advanced Solid Tumors | terminated | Phase 1 | 28 | PfizerINDUSTRY | 1 | May 6, 2020 | clinicaltrials |
| NCT02603419 | Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) | terminated | Phase 1 | 34 | PfizerINDUSTRY | 3 | Apr 24, 2020 | clinicaltrials |
| NCT01212991 | A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer(PREVAIL) | completed | Phase 3 | 1,717 | PfizerINDUSTRY | 22 | Mar 17, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT01546038 | A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 255 | PfizerINDUSTRY | 6 | Mar 3, 2020 | clinicaltrials |
| NCT02764151 | First in Patient Study for PF-06840003 in Malignant Gliomas | terminated | Phase 1 | 17 | PfizerINDUSTRY | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03159117 | Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma | completed | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03042910 | A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors | completed | Phase 1 | 38 | PfizerINDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02954653 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 8 | PfizerINDUSTRY | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00878189 | A Trial In Patients With Advanced Cancer And Leukemia | completed | Phase 1 | 72 | PfizerINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT03220230 | Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.(NIRVANA) | completed | — | 4,240 | PfizerINDUSTRY | 3 | Nov 8, 2019 | clinicaltrials |
| NCT00640692 | Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial | withdrawn | — | 0 | Oregon Health and Science UniversityOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT00721409 | Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer | completed | Phase 2 | 177 | PfizerINDUSTRY | 12 | Nov 4, 2019 | clinicaltrials |
| NCT03178071 | Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive | no longer available | — | — | PfizerINDUSTRY | 1 | Nov 4, 2019 | clinicaltrials |
| NCT02187042 | Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line(RENACALL) | completed | — | 70 | PfizerINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02034916 | A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)(ABRAZO) | terminated | Phase 2 | 84 | PfizerINDUSTRY | 5 | Oct 14, 2019 | clinicaltrials |
| NCT00510718 | A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer | completed | Phase 1 | 140 | PfizerINDUSTRY | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01597258 | Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan) | completed | — | 2,029 | PfizerINDUSTRY | 0 | Sep 13, 2019 | clinicaltrials |
| NCT02312037 | Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy(AML) | no longer available | — | — | PfizerINDUSTRY | 1 | Aug 20, 2019 | clinicaltrials |
| NCT01055496 | Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | completed | Phase 1 | 103 | PfizerINDUSTRY | 9 | Aug 2, 2019 | clinicaltrials |
| NCT01525550 | A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | completed | Phase 4 | 106 | PfizerINDUSTRY | 15 | Jul 30, 2019 | clinicaltrials |
| NCT02315755 | Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC | completed | — | 102 | PfizerINDUSTRY | 1 | Jul 26, 2019 | clinicaltrials |
| NCT02304406 | Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa(ALK NSCLC MENA) | completed | — | 449 | PfizerINDUSTRY | 5 | Jul 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials